Spain’s Pharma Industry Diagnosis & Treatment
- Research adn innovation are increasingly vital to the European economy, especially in the health and pharmaceutical sectors, according to participants at a recent colloquium.
- The colloquium centered on innovation's role as an economic driver for Europe and the strategic and regulatory challenges affecting its progress.
- The event, moderated by José María López Alemany, was supported by Lilly, MSD, Novartis, and Pfizer.
European Economy Hinges on Health Innovation, Experts Say
Table of Contents
- European Economy Hinges on Health Innovation, Experts Say
- European Economy Hinges on Health Innovation: Your Questions Answered
- what Role Does Innovation Play in the European Economy?
- What are the Key Challenges Facing the Spanish pharmaceutical Industry?
- How Does Productivity in Spain Compare to Other European Countries?
- Why is Productivity Such a Significant Issue?
- What Impact Have Generics Had on the Pharmaceutical Sector?
- What are the Key Messages from Victor Ausín’s Analysis?
- What Are the Strategic Risks and Opportunities Associated with the European Pharmaceutical Industry?
- Why is a Robust European pharmaceutical Industry Necessary?
- What Did Thomas Allvin Emphasize?
- Table: Key Differences in Pharmaceutical Sector Performance
- What Can the Spanish Pharmaceutical industry Do to Improve?
Research adn innovation are increasingly vital to the European economy, especially in the health and pharmaceutical sectors, according to participants at a recent colloquium. The event,titled “Research and Innovation as Key Factors of the European Economy,” was part of a series examining the impact of European legislative actions on spain’s health and pharmaceutical industry.
The colloquium centered on innovation’s role as an economic driver for Europe and the strategic and regulatory challenges affecting its progress.
Attendees included Victor Ausín, General Director of Economic Policy of the Ministry of Economy; Daniel Ruiz iruela, Deputy Director General of International Research and Institutional Relations Programs at the Carlos III Health Institute; Juan Yermo, General Director of Farmaindustria; Alvaro Hidalgo, Director of the Health and Health Economics research Group of the University of Castilla-La Mancha and President of Weber; and Jesús García Foncillas, president of the ECO Foundation. Thomas Allvin, Director of Strategy of the European Federation of Pharmaceutical Industries (EFPIA), participated via videoconference.
The event, moderated by José María López Alemany, was supported by Lilly, MSD, Novartis, and Pfizer.
Spanish Pharmaceutical Industry Faces Productivity Challenges
Victor Ausín presented an analysis of the pharmaceutical sector, noting its potential but also its stagnant productivity despite critically important investment. He compared the Spanish pharmaceutical industry to its European counterparts, highlighting strengths and weaknesses. He also examined the economic impact of generic medicines on the sector.
Ausín’s analysis included a macroeconomic comparison of the pharmaceutical sector across different countries, considering factors such as Gross added Value (GVA), productivity, employment, billing, costs, margins, and company size. He concluded that Sweden’s manufacturing industry is the most strategic. He noted similarities between the Spanish and French industries, as well as between the Italian and German industries. France, he said, has fewer but larger companies. Regarding employment,Ausín stated,”the idea is to be very productive,be very high in GVA and very low in employment.”
ausín argued that Spain’s primary challenge is its inability to effectively translate work into productivity. He contrasted this with France, which demonstrates a greater capacity to generate productivity with less weight in GVA.spain relies heavily on salary compression, while Sweden excels in product quality and branding. Ausín emphasized that competitiveness should stem from productivity rather than salary reduction.
He noted that most countries experienced productivity growth in the pharmaceutical sector between 2008 and 2022,except for Spain and Portugal. France considerably increased productivity through business consolidation, achieving synergy and economies of scale. Italy, similar to Germany, effectively transforms investments into intangible assets and salaries in terms of productivity. Despite considerable investment in tangible and intangible assets,including R&D,Spain struggles to generate revenue,indicating a “productivity problem,” according to Ausín.
Ausín emphasized that Spain’s sector competitiveness relies on salary containment rather than productivity. The salary differential between the pharmaceutical sector and the industrial average has decreased from 70% above the industry average in 2008 to 35% currently. Export growth has not been matched by proportional productivity gains.
Generics Impact on Investment
The shift in salary structure began around 2008, transitioning from extensive to intensive production. The growth of generic medicines has been pivotal, containing public spending and creating surpluses in the pharmaceutical trade balance. However, it has also discouraged investment in intangible assets like patents, brands, and organizational innovation.Ausín analyzed the implications of legally promoting generic versus brand medications, noting that encouraging generic purchases has reduced national margins.
Capital investment patterns have also shifted. As 2000, the sector had increased its focus on immaterial assets, but this trend reversed after the expansion of generics and the 2008 financial crisis. Investment has since been redirected towards material assets like production plants and machinery,limiting productivity growth.
Despite these challenges, Ausín believes the financial situation of companies remains solid, with low debt and high self-financing capacity.However, profitability remains low compared to other European countries due to the difficulty in converting available resources into intangible added value.
Ausín concluded with three key messages: Spain needs to boost productivity in its pharmaceutical industry to align with other European countries; the sector has the potential to grow and differentiate, particularly through brand investment and vertical differentiation; and R&D investment should extend beyond clinical aspects to encompass the entire business model, including promotion, institution, expansion, and knowledge management.
Strategic Risks and Opportunities
Following Ausín’s presentation, participants discussed the consequences of Europe failing to establish an innovative and competitive pharmaceutical industry. Experts agreed that the risks are not only economic but also strategic, health-related, and social.
Ausín reiterated that the challenge is to compete on productivity rather than costs. He believes that broad innovation encompassing processes, business management, and training is the only way to improve competitiveness without relying on salary compression.
Allvin emphasized the need for a robust European pharmaceutical industry to ensure access to innovative medicines. He highlighted the importance of collaboration between industry, academia, and regulatory bodies to foster innovation and address unmet medical needs.
European Economy Hinges on Health Innovation: Your Questions Answered
The European economy, especially its health and pharmaceutical sectors, is undergoing notable changes. Let’s dive into the key challenges, opportunities, and strategic considerations impacting innovation and productivity, based on insights from a recent colloquium.
what Role Does Innovation Play in the European Economy?
Innovation is a critical driver of the European economy, especially in the health and pharmaceutical sectors. The colloquium, “Research and Innovation as Key Factors of the European Economy”, highlighted that legislative actions and strategic approaches greatly effect the progress of these sectors.
What are the Key Challenges Facing the Spanish pharmaceutical Industry?
One of the main challenges highlighted is stagnant productivity. despite significant investment, the Spanish pharmaceutical industry lags behind some of its European counterparts in translating investment into tangible results. A key issue is the inability to convert work into productivity effectively.
How Does Productivity in Spain Compare to Other European Countries?
spain struggles to generate revenue from investments, including R&D, compared to countries like France and Sweden. Sweden’s manufacturing industry is seen as strategic, excelling in product quality and branding. France has increased productivity through business consolidation. Countries like Italy and Germany adeptly translate investments into intangible assets,contributing to productivity.In contrast, Spain’s competitiveness frequently enough relies on salary containment rather of productivity gains.
Why is Productivity Such a Significant Issue?
Productivity growth ensures competitiveness and economic health without needing to rely on salary compression. It allows companies to compete on value and innovation rather than simply cutting costs. The ability to transform work and investment into tangible outputs is crucial for long-term growth.
What Impact Have Generics Had on the Pharmaceutical Sector?
The rise of generic medicines has impacted the industry by containing public spending and creating trade surpluses.Though, it has also discouraged investment in intangible assets such as patents, brands, and organizational innovation. The shift towards generics has influenced capital investment patterns. Since around 2000, the sector’s emphasis on immaterial assets was reversed after the expansion of generics and the 2008 financial crisis, with investment redirected towards tangible assets like production plants and machinery.
What are the Key Messages from Victor Ausín’s Analysis?
Victor Ausín, General Director of Economic Policy of the Ministry of Economy, concluded with three key messages:
- Spain needs to substantially boost productivity in its pharmaceutical industry by aligning with its European counterparts.
- The sector has the potential to grow and differentiate, and should focus on brand investment and vertical differentiation.
- R&D investment should extend beyond clinical aspects to encompass the entire business model, including promotion, institution, expansion, and knowledge management.
What Are the Strategic Risks and Opportunities Associated with the European Pharmaceutical Industry?
Experts believe risks are present not only economically but also strategically, health-related, and socially. The possibility lies in emphasizing productivity over cost-cutting through broad, inclusive innovation.
Why is a Robust European pharmaceutical Industry Necessary?
A robust European pharmaceutical industry is vital to ensure access to innovative medicines.Collaboration among industry,academia,and regulatory bodies is crucial to foster innovation and meet unmet medical needs.This collaboration can help develop new therapies and improve patient outcomes.
What Did Thomas Allvin Emphasize?
Thomas Allvin, via teleconference, highlighted that the European pharmaceutical industry must ensure access to innovative medicines. He emphasized the importance of collaboration between industry, academia, and regulatory bodies to foster innovation and address unmet medical needs. Such collaboration is key to driving progress.
Table: Key Differences in Pharmaceutical Sector Performance
| Country | Key Strength | Challenges |
|---|---|---|
| Spain | strong export growth. | Low productivity growth, reliance on salary compression |
| France | Business consolidation, economies of scale. | Generating productivity with less weight in GVA. |
| Sweden | Product quality and branding. | Limited information in source. |
| Italy/Germany | effectively transform investments into intangible assets and salaries in terms of productivity | Limited information in source. |
What Can the Spanish Pharmaceutical industry Do to Improve?
The industry can aim for more investment in intangible assets.The sector should prioritize productivity over cost containment, investing in brand and differentiating efforts. Focusing on R&D should extend beyond clinical aspects, encompassing all business model components. This can help the industry to grow and differentiate itself.
This Q&A format aims to provide a thorough understanding of the challenges and opportunities within the European pharmaceutical industry, emphasizing the need for innovation, productivity, and strategic collaborations.